121 related articles for article (PubMed ID: 32189027)
1. Dynamic whole-body
Nishimura M; Tamaki N; Matsushima S; Kiba M; Kotani T; Bamba C; Nakamura Y; Yamada K
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2293-2300. PubMed ID: 32189027
[TBL] [Abstract][Full Text] [Related]
2. Comparison between dynamic whole-body FDG-PET and early-delayed imaging for the assessment of motion in focal uptake in colorectal area.
Kotani T; Nishimura M; Tamaki N; Matsushima S; Akiyama S; Kanayama T; Bamba C; Tanada Y; Nii T; Yamada K
Ann Nucl Med; 2021 Dec; 35(12):1305-1311. PubMed ID: 34426890
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
5. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
6. Does whole-body Patlak
Fahrni G; Karakatsanis NA; Di Domenicantonio G; Garibotto V; Zaidi H
Eur Radiol; 2019 Sep; 29(9):4812-4821. PubMed ID: 30689031
[TBL] [Abstract][Full Text] [Related]
7. Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose-positron emission tomography to differentiate between benign and malignant lesions.
Watanabe M; Kato H; Katayama D; Soeda F; Matsunaga K; Watabe T; Tatsumi M; Shimosegawa E; Tomiyama N
Ann Nucl Med; 2022 Nov; 36(11):951-963. PubMed ID: 36057012
[TBL] [Abstract][Full Text] [Related]
8. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
[TBL] [Abstract][Full Text] [Related]
9. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
Yun M; Choi HS; Yoo E; Bong JK; Ryu YH; Lee JD
J Nucl Med; 2005 Jun; 46(6):953-7. PubMed ID: 15937305
[TBL] [Abstract][Full Text] [Related]
10. Improvement of motion artifacts using dynamic whole-body
Kaji T; Osanai K; Takahashi A; Kinoshita A; Satoh D; Nakata T; Tamaki N
Jpn J Radiol; 2024 Apr; 42(4):374-381. PubMed ID: 38093138
[TBL] [Abstract][Full Text] [Related]
11. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
12. Dual-time-point (18)F-FDG-PET/CT imaging in the assessment of suspected malignancy.
Chan WL; Ramsay SC; Szeto ER; Freund J; Pohlen JM; Tarlinton LC; Young A; Hickey A; Dura R
J Med Imaging Radiat Oncol; 2011 Aug; 55(4):379-90. PubMed ID: 21843173
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
14. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of positive and negative oral contrast agents on (18)F-FDG PET/CT scan.
Sun XG; Huang G; Liu JJ; Wan LR
Hell J Nucl Med; 2009; 12(2):115-8. PubMed ID: 19675862
[TBL] [Abstract][Full Text] [Related]
16. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
17. Defining optimal tracer activities in pediatric oncologic whole-body
Gatidis S; Schmidt H; la Fougère C; Nikolaou K; Schwenzer NF; Schäfer JF
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2283-2289. PubMed ID: 27565153
[TBL] [Abstract][Full Text] [Related]
18. Characterization of pulmonary lesions with low F-18 FDG uptake using double phase F-18 FDG PET/CT: comparison of visual and quantitative analyses.
Kim IJ; Kim SJ; Kim YS; Lee TH; Jeong YJ
Neoplasma; 2009; 56(1):33-9. PubMed ID: 19152243
[TBL] [Abstract][Full Text] [Related]
19. Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population.
Naganawa S; Yoshikawa T; Yasaka K; Maeda E; Hayashi N; Abe O
Medicine (Baltimore); 2017 Nov; 96(46):e8832. PubMed ID: 29145346
[TBL] [Abstract][Full Text] [Related]
20. A novel objective method for discriminating pathological and physiological colorectal uptake in the lower abdominal region using whole-body dynamic
Kato T; Ichikawa H; Shibutani T; Kita A; Watanabe M; Tada H; Sugiura A
Ann Nucl Med; 2023 Oct; 37(10):561-571. PubMed ID: 37523072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
